SEC Form 4 · accession 0001553878-18-000027

ALNYLAM PHARMACEUTICALS, INC. · ALNY

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President, R&D

Period of report

Mar 14, 2018

Accepted (ET)

Mar 16, 2018 · 5:05 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001178670

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Mar 14, 2018	M	44,641	$18.66	A	55,856	D
Common Stock	Mar 14, 2018	M	38,913	$16.43	A	94,769	D
Common Stock	Mar 14, 2018	M	5,000	$7.10	A	99,769	D
Common Stock^F2	Mar 14, 2018	S	6,453	$140.45	D	93,316	D
Common Stock^F3	Mar 14, 2018	S	15,000	$141.69	D	78,316	D
Common Stock^F4	Mar 14, 2018	S	21,336	$142.57	D	56,980	D
Common Stock^F5	Mar 14, 2018	S	19,213	$143.46	D	37,767	D
Common Stock^F6	Mar 14, 2018	S	20,172	$144.53	D	17,595	D
Common Stock^F7	Mar 14, 2018	S	6,380	$145.27	D	11,215	D
Common Stock^F8	holding	—	—		—	338	I	by Managed Account

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Stock Option (right to buy)^F9	$7.10	Mar 14, 2018	M	5,000	D	—	Nov 30, 2021	Common Stock	5,000	D
Stock Option (right to buy)^F9	$16.43	Mar 14, 2018	M	38,913	D	—	Dec 9, 2019	Common Stock	38,913	D
Stock Option (right to buy)^F9	$18.66	Mar 14, 2018	M	44,641	D	—	Dec 20, 2022	Common Stock	44,641	D

F1All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2018.
F2Sale prices ranged from $140.00 to $140.95
F3Sale prices ranged from $141.01 to $142.00
F4Sale prices ranged from $142.01 to $143.00
F5Sale prices ranged from $143.01 to $143.98
F6Sale prices ranged from $144.01 to $145.00
F7Sale prices ranged from $145.01 to $145.80
F8The reporting person owns 338 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
F9The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.